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We examined the expression of ephrin-B1 and its cognate receptor EphB2, key regulators of angiogenesis and embryogenesis, in
human abdominal aortic aneurysm (AAA) and analyzed their functional roles in cell migration. From 10 patients (9 males and
1 female; age, 68.5 ± 2.4) who underwent vascular surgery for AAA, we obtained AAA and adjacent control tissues. Using real-
time RT-PCR, we analyzed expression of ephrin-B1 and EphB2. We also histologically localized these molecules in AAA tissues.
Finally, eﬀects of ephrin-B1 and EphB2 on inflammatory cell chemotaxis were examined by cell migration assay. Expression levels
of ephrin-B1 (0.410 ± 0.046 versus 1.198 ± 0.252, P = 0.027) and EphB2 (0.764 ± 0.212 versus 1.272 ± 0.137, P = 0.594) were
higher in AAA than normal control. Both ephrin-B1 and EphB2 were expressed in macrophages, T lymphocytes, and endothelial
cells within AAA. In chemotaxis assay, ephrin-B1 and EphB2 inhibited mononuclear-cell chemotaxis induced by stromal derived
factor-1 down to 54.7±12.7% (P = 0.01) and 50.7±13.1% (P = 0.01), respectively. These data suggest that ephrin-B1 and EphB2
might be functional in human adult inflammatory cells and involved in the pathogenesis of AAA, although specific roles of these
molecules should further be sought.
1. Introduction
Abdominal aortic aneurysm (AAA) has high risk for aortic
rupture and constitutes one of the major causes of elderly
death [1], sometimes being associated with coronary ectasia
[2]. Compared to occlusive atherosclerosis such as carotid
atheroma, AAA aﬀects much more extensive layers of blood
vessels but shares some pathogenic aspects such as inflam-
matory cell accumulation [3]. Genetically engineered mouse
models for AAA have elucidated key molecules for the
pathogenesis of AAA [4]. For example, some matrix met-
alloproteinases (MMPs) are upregulated and expressed in
macrophages within AAA, which is likely to cause medial
degeneration in AAA [5] with or without physiological stress
such as hypoxia [6]. However, our understanding on the
molecular and cellular pathogenesis of AAA is still limited,
especially in cases of humans.
Recently, we have found that ephrin-B1 and its cog-
nate receptor EphB2, the key regulators of angiogenesis
and embryogenesis, are upregulated and predominantly
expressed in macrophages and T-lymphocytes in human
carotid atherosclerotic plaque [6]. Ephrin-B1 and EphB2
belong to ephrin and Eph family of genes consisting 21mem-
bers, which are expressed ubiquitously in embryonic tissues
and involved in morphogenesis by regulating cell adhesion
and migration [7, 8]. Therefore, we hypothesized that
ephrin-B1 and EphB2 might be also involved in the patho-
genesis of AAA and set out to analyze the expression of these
molecules in human AAA and their modulatory eﬀects on
chemotaxis of inflammatory cells.
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2. Methods
2.1. Patients. The experimental protocol complied with the
principles of the Declaration of Helsinki and was approved
by the ethical committee of National Cerebral and Cardiovas-
cular Center. Written informed consent was obtained from
all the 10 patients who underwent elective graft replacement
surgery for AAA (9 males and 1 female; age, 68.5 ± 2.4) [9].
None of the AAA patients suﬀered from clinically unstable
state such as aortic rupture before surgery. The diameter of
AAA measured by computed tomography ranged from 38 to
80mm (55.3 ± 3.5mm). The prevalence of risk factors for
AAA was as follows: hypertension in 9, hyperlipidemia in 8,
smoking in 7, and diabetes mellitus in 2 out of 10 patients.
2.2. Aortic Tissue Sampling. During graft replacement for
AAA, a strip of aortic wall that contained the dilated region
and lacked mural thrombus was carefully excised. An infra-
renal aortic strip which contained minimal atherosclerotic
changes without dilation was also obtained from five patients
as control. All the samples were quickly frozen in liquid
nitrogen and stored at−80◦C until extraction of RNA. A part
of the tissue was fixed with non-formalin-fixative solution,
Histochoice (Amresco, Solon, OH), and embedded in paraf-
fin.
2.3. Antibodies and Reagents. For immunohistochemistry, we
used the followingmousemonoclonal antibodies: anti-CD68
(clone KP1) (Dako, Glostrup, Denmark) and anti-CD8
(clone 4B11) (Novocastra, Newcastle, UK). The following
polyclonal antibodies were employed: rabbit anti-ephrin-
B1 (Santa Cruz, Santa Cruz, CA); goat anti-EphB2 (Sigma,
St. Louis, MO); rabbit anti-von Willebrand Factor (vWF)
(Dako); rabbit anti-CXCR-4 (Sigma-Aldrich, St. Louis, MO).
Biotinylated swine anti-goat IgG (Dako) was also used. The
following recombinant proteins were used: human stromal-
derived factor-1 (SDF-1) (PeproTech, London, UK); human
monocyte chemotactic protein-1 (MCP-1) (BioLegend, San
Diego, CA); mouse ephrin-B1-IgG-Fc chimera and mouse
EphB2-IgG-Fc chimera (R&D Systems, Minneapolis, MN);
IgG-Fc (Athens Research & Technology, Athens, GA).
2.4. Quantitative Reverse Transcription-Polymerase Chain
Reaction (Quantitative RT-PCR). Total RNA was isolated
from the aortic specimens using Isogen reagent (Nippon
Gene, Tokyo, Japan) according to themanufacturer’s instruc-
tions [10]. Concentration of the RNA was measured with
spectrophotometer and its integrity was confirmed visually
on 1.2% denaturing agarose gel electrophoresis stained with
SYBR Green dye (Invitrogen, Carsbad, CA). Then, 10 μg of
total RNAwas treated with DNA-free agent (Ambion, Austin,
TX) and converted to cDNA using random primers and
SuperScript II reverse transcriptase (Invitrogen). Quanti-
tative RT-PCR was performed using TaqMan reagents on
ABI Prism 7700 Sequence Detection System (PE Applied
Biosystems, Foster City, CA). Assay-on-Demand cock-
tails (PE Applied Biosystems) were used for ephrin-
B1 (Hs00270004 m1) and EphB2 (Hs00362096 m1). For
GAPDH, predeveloped TaqMan assay reagent was used. The
expression levels of ephrin-B1 or EphB2 were normalized to
those of GAPDH as described previously [5, 11].
2.5. Immunohistochemistry. The paraﬃn-embedded speci-
mens of AAA were sectioned in 3 μm thickness. These sec-
tions were deparaﬃnized with Neo-Clear (Merk, Darmsdat,
Germany). For histopathological evaluation, the sections
were stained with hematoxylin and eosin (H&E). For double
immunohistochemical staining of ephrin-B1 and CD68,
ephrin-B1 and CD8, ephrin-B1 and vWF, or ephrin-B1 and
CXCR-4, the sections were first incubated with anti-ephrin-
B1 antibody (1 : 300 dilution) and indirectly stained as brown
precipitates using peroxidase-coupled Envision system (PO-
Envision, Dako) and 3, 3′-diaminobenzidine (DAB) as sub-
strate. Subsequently, the same sections were incubated with
anti-CD68 (1 : 300 dilution), anti-CD8 (1 : 40 dilution), anti-
vWF (1 : 200 dilution), or anti-CXCR4 (1 : 100 dilution)
antibodies and stained as red precipitates using alkaline
phosphatase-coupled Envision system (AP-Envision, Dako)
and New Fuchsin (Dako) as substrate.
For double immunostaining of EphB2 and CD68, EphB2
and CD8, EphB2 and vWF, or EphB2 and CXCR-4, sections
were first incubated with goat anti-EphB2 antibody (1 : 50
dilution) and processed with peroxidase-coupled Histofine
MAX-(G) system (Nichirei, Tokyo, Japan) and DAB. The
same sections were then incubated with anti-CD68, anti-
CD8, anti-vWF, or anti-CXCR4 antibodies and processed
with AP-Envision and New Fuchsin. Before the double
immunohistochemistry for ephrin-B1 and CD8 or EphB2
and CD8, the sections had been autoclaved in 0.01mol/L cit-
rate buﬀer (pH 6.0) for 5 minutes at 121◦C to unmask CD8
antigen. For double immunostaining of CD68 and CXCR-
4, the sections were first incubated with anti-CD68 antibody
and processed with PO-Envision and DAB. The same
sections were then incubated with anti-CXCR-4 antibody
and processed with AP-Envision and New Fuchsin. All
these preparations were counterstained with hematoxylin,
mounted with Neo-Mount (Merk), and examined with
Axiophot2 light microscope equipped with AxioCam CCD
camera (Carl Zeiss, Hallbergmoos, Germany).
2.6. RT-PCR for Ephrin-B1 and EphB2 in Peripheral Blood
Mononuclear Cells. Human peripheral blood mononuclear
cells (PBMC) were prepared from forearm venous blood of
healthy adult volunteers by density-gradient centrifugation
through Lymphoprep (Axis-Shield PoC AS, Oslo, Norway).
From the human PBMC, total RNA was isolated with Isogen
reagent, which was cleared of con-taminating genomic
DNA and reversely transcribed to cDNA using QuantiTect
Reverse Transcription Kit (Qiagen, Hilden, Germany). For
RT-PCR, the forward and reverse primers were designed
within a single exon of ephrin-B1 (exon 5) or EphB2
(exon 6) : ephrin-B1, 5′-GTCCTACTACTGAAGCTACG-
3′/5′-CTCTTGGACGATGTAGACAG-3′ ; EphB2, 5′-
GCAGTGTCCATCATGCATC-3′/5′-AGTACTGCAGCT-
CATAGTCC-3′.
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As negative and positive controls, the DNA-cleared RNA
without reverse transcription and human genomic DNA
(50 nM; Clontech, Palo Alto, CA) were used, respectively. The
reaction mixture was assembled to a total volume of 10 μL as
follows: 6.65 μLwater, 1.0 μL 10× Ex Taq buﬀer, 0.8 μL dNTP
mixture (comprising 2.5mM of each nucleotide), 1.0 μL
forward and reverse primer mixture (5 μM of each primer),
0.5 μL template, and 0.05 μL Ex Taq polymerase (TaKaRa,
Tokyo, Japan). The PCR was carried out with preheating
(94◦C for 2min) and 35 cycles of amplification (94◦C for
20 s, 60◦C for 30 s and 72◦C for 40 s). The PCR products were
subjected to acrylamide gel electrophoresis and stained with
Ethidium bromide. The experiments were performed at least
three times and the representative data are shown.
2.7. Cell Migration Assay. Boyden chamber cell migration
assay was performed using 24-well Transwell plates which
contain, in each well, a chamber with 5 μm porous polycar-
bonate membrane separating the well into upper and lower
parts (Corning, Corning, NY). The chamber membranes
were precoated with ephrin-B1-Fc, EphB2-Fc, or IgG-Fc
as control (5 μg/mL, overnight). Then the chambers were
inserted into Transwell plates containing 600 μL of assay
buﬀer (RPMI1640 medium with 0.1% heat-inactivated BSA)
with or without chemokines (SDF-1 orMCP-1 at 0.1 μg/mL).
Human PBMC (1 × 105 cells in 100 μL of the assay buﬀer)
were loaded into the chamber and allowed to migrate down
to the lower part of the well for 2 hours in a humidified
incubator (37◦C; 5% CO2). After the migration period, the
PBMC that had passed down through the membrane were
collected and counted using Z2 Coulter counter (Beckman
Coulter, Fullerton, CA). Under the same condition, we also
tried to use soluble recombinant ephrin-B1 and EphB2
diluted into the medium to assess the cell migration, because
there were some reports that demonstrated diﬀerences in
results of cell migration [12].
2.8. Statistical Analysis. The results of Quantitative RT-PCR
and Boyden chamber assay were expressed as mean ± SEM
of two independent experiments done in triplicate. All
statistical analyses were performed by using StatView Ver.5.0
software (SAS Institute Inc, Cary, NC). A value of P < 0.05
was considered to be statistically significant.
3. Results
3.1. Expression of Ephrin-B1 and EphB2 in Human AAA.
All the total RNA isolated from AAA or control aortas
maintained robust integrity on agarose gel electrophoresis,
ensuring reliable analysis of gene expression. Quantitative
real-time RT-PCR showed that ephrin-B1 was significantly
upregulated in AAA than in control (Figure 1). As for EphB2,
a trend toward higher expression in AAA was observed,
although the data did not reach statistical significance.
3.2. Immunohistochemical Analysis of Ephrin-B1 and EphB2
in Human AAA Lesions. Each of the tissue specimens used




























Figure 1: Quantitative real-time RT-PCR analysis of ephrin-B1 and
EphB2 in human AAA. The results are mean ± SEM (n = 10) and
were analysed by an unpaired Student’s t-test.
layers of aorta were aﬀected and the tunica media were
severely damaged (Figure 2(a)). Prominent fatty streaks and
inflammatory cell infiltration were observed in the intima
(Figure 2(b)). Under these conditions, the presence of these
inflammatory cells was apparently greater in AAA tissues
than those in controls. We performed double immunohis-
tochemical staining to clarify the precise cell types expressing
ephrin-B1 or EphB2 therein, because we found that ephrin-
B1 and EphB2 were expressed in various types of cells within
human AAA with single immunostaining.
Immunoreactivity of ephrin-B1 was found in the follow-
ing cell types: macrophages positive for CD68 [13] (Figure
2(c)); lymphocytes positive for CD8 [14] (Figure 2(d));
endothelial cells positive for vWF [15] (Figure 2(e)). Simi-
larly, EphB2 was detected in macrophages positive for CD68
(Figure 3(a)), lymphocytes positive for CD8 (Figure 3(b)),
and endothelial cells positive for vWF (Figure 3(c)).
To investigate functional significance of ephrin-B1 and
EphB2 on chemotaxis of macrophages or lymphocytes, we
examined coexpression of these molecules with CXCR4, a
receptor for SDF-1 [16] by double immunohistochemistry.
Many macrophage- or lymphocyte-like cells were found to
express both ephrin-B1 and CXCR4 (Figure 2(f)) or both
EphB2 and CXCR4 (Figure 3(d)).
3.3. Functional Expression of Ephrin-B1 and EphB2 in Periph-
eral Blood Mononuclear Cells. To confirm the expression
at mRNA levels of ephrin-B1 and EphB2 on human adult
inflammatory cells, we performed RT-PCR. In human
PBMC, both ephrin-B1and EphB2 were robustly expressed
(Figure 4). We then tested whether ephrin-B1 and EphB2
have functional importance in human PBMC, by examining
the eﬀects of ephrin-B1 and EphB2 on their chemotaxis.
In Boyden chamber assay, membrane-coated ephrin-B1-Fc
or EphB2-Fc chimeric proteins did not aﬀect spontaneous







Figure 2: Histology of human AAA and double immunostaining of ephrin-B1 and others therein. (a) I, intima; M, tunica media; A,
adventitia. Note severely destructed tunica media. Bars, 200 μm. (b) Arrow indicates fatty streak in intima. Bars, 20 μm. (c) and (d) Double
immunostaining. Ephrin-B1 was stained with DAB (brown), the others with New Fuchsin (red). Bars, 20 μm.
migration of PBMC (Figure 5(a)). However, the chemotaxis
of PBMC induced by SDF-1 was significantly inhibited by
ephrin-B1-IgG-Fc and EphB2-IgG-Fc down to 54.7 ± 12.7%
(P = 0.01) and 50.7 ± 13.1% (P = 0.01), respectively
(Figure 5(b)). Also, MCP-1-induced chemotaxis of PBMC
was significantly inhibited by ephrin-B1-IgG-Fc and EphB2-
IgG-Fc down to 53.8 ± 10.9% (P = 0.01) and 51.3 ± 11.6%
(P = 0.01), respectively, although no significant increases or
decreases of cell migration were observed in cases of soluble
ephrin-B1 and EphB2.
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Figure 3: Double immunostaining of EphB2 and others in human AAA. EphB2 was stained with DAB (brown), the others with New Fuchsin




Figure 4: RT-PCR analysis for ephrin-B1 and EphB2 in human
PBMC. Three kinds of templates were used to validate the results:
lane 1, cDNA; lane 2, DNA-cleared RNA; lane 3; genomic DNA.
4. Discussion
We found that both ephrin-B1 and EphB2 exhibited higher
expression in human AAA and were expressed in macro-
phages, T lymphocytes, and endothelial cells therein. Fur-
thermore, we found that membrane-bound ephrin-B1 and
EphB2 inhibited chemotaxis of human PBMC in Boyden
chamber assay. Ephrins and their cognate receptor Ephs are
well-known regulators in embryogenesis [7, 8] but their
expressions and pathogenic roles in AAA remain unclear.
Therefore, the findings of this study would give us a new clue
to investigate the molecular pathogenesis of human AAA.
One major cause of higher expression of ephrin-B1 and
EphB2 in AAA is probably the infiltration therein of macro-
phages and T-lymphocytes expressing these two genes.
However, gene expression levels of ephrin-B1 and EphB2
in monocytes/macrophages, T-lymphocytes, and endothelial
cells in AAA might be upregulated, which remains to be elu-
cidated. Taken together with the fact that ephrin-A5 is upreg-
ulated in human AAA [17], wide spectrum of ephrins and
Ephs [7] might be upregulated in human AAA. We further
tested whether ephrin-B1 and EphB2 are functional or
nonfunctional on human adult inflammatory cells. For this
purpose, we examined the eﬀects of ephrin-B1 and EphB2
on chemotaxis, because these molecules are well known to
regulate migration of embryonic cells. In Boyden chamber
assay, the membrane-fixed ephrin-B1 inhibited chemo-
taxis of human PBMC induced by SDF-1 or MCP-1, which
is in line with the previous reports that ephrin-B1 inhibits
SDF-1-induced chemotaxis of Jurkat T-lymphocytic [18]
and THP-1 monocytic cell lines [6].

























































Figure 5: Modulatory eﬀects of ephrin-B1 and EphB2 on transmigration of human PBMC by SDF-1. Boyden chamber assay was performed.
(a) Eﬀect of ephrin-B1 or EphB2 on spontaneous transmigration. The number of cells migrating into the well without SDF-1 was considered
spontaneous transmigration. (b) Eﬀect of ephrin-B1 or EphB2 on SDF-1-induced transmigration.With SDF-1, the increased number of cells
migrating into the well was due to SDF-1-dependent transmigration. The level of PBMC migration with IgG-Fc used as control, which was
3.6% (a) and 18.5% (b) of inputs (1× 105 cells), was set at 100% for analysing the eﬀect of ephrin-B1 or EphB2. Ephrin-B1, ephrin-B1-IgG-
Fc; EphB2, EphB2-IgG-Fc. The results are mean ± SEM (n = 6) and were analysed by one factor ANOVA and Dunnett’s test compared with
IgG-Fc (control).
The chemotaxis of human PBMC induced by SDF-1 or
MCP-1 was also inhibited by the membrane-fixed EphB2,
which usually functions as receptor. This ligand-like action
by EphB2 is considered so-called reverse signalling [8], like
EphB2 inhibiting SDF-1-dependent migration of cerebellar
granule cell of mouse embryo [19]. In addition, there are
several reports which show ephrin signalling interacts with
inflammatory molecules such as Rho family GTPases [20]
and VCAM-1 [21]. Thus, our findings from Boyden chamber
assay suggest that ephrin-B1 and EphB2 on human PBMC
are functional.
Importantly, these inhibitory eﬀects of ephrin-B1 and
EphB2 were not clearly observed when we used soluble
agents. This may be partially explained by a dependence of
Eph receptor activation on lateral movement across the cell
membrane for complete activity [12]. Pfaﬀ et al. [22] demon-
strated lateral movement of endothelial ephrinB2 from the
apical surface to cell-cell junctions preceding degradation.
Additionally, one might speculate that ephrins/eph receptors
fixed to transwell membranes may not induce proper spatial
distribution of counter-receptors/ligands for chemotaxis.
However, the present data demonstrate at least the inhibitory
eﬀects of cell migration induced by SDF-1 in vitro.
Including cytokines and chemokines, most of the known
factors that regulate the activities of macrophages or T-
lymphocytes are soluble molecules which are widely spread
[23]. In contrast, ephrins and Ephs are membrane-bound
molecules which exert their functions locally through cell-
to-cell interaction with their neighbouring cells [24]. During
the pathological courses of many inflammatory diseases
including AAA [25–29], various types of cell-to-cell inter-
action occur: macrophages-to-macrophages, macrophages-
to-T-lymphocytes, macrophages-to-endothelial cells, and so
on. Ephrin-B1 and EphB2, or more generally ephrins and
Ephs, might locally and precisely modulate the activities of
macrophages and T-lymphocytes conditioned by diﬀusing
factors such as cytokines and chemokines. Understanding the
eﬀect of ephrinB1 or EphB2 activation on the inflammatory
condition, perhaps to MMP expression or function, may
make clear the role of ephrinB1 or EphB2 in this context [30].
Interestingly, we recently found that ephrin and Eph family
are widely expressed in atherosclerosis-related cells in human
[31]. Further study will elucidate the in vivo roles of ephrins
and Ephs in the development of atherosclerosis, both dilated
and occlusive, and other inflammatory diseases.
5. Conclusions
This study suggests that ephrin-B1 and EphB2, the key
embryogenic regulators, might be involved in the molecular
and cellular pathogenesis of human AAA. Through cell-to-
cell interactions, ephrin-B1 and EphB2 might locally mod-
ulate the inflammatory cell activities conditioned by soluble
mediators such as cytokines. Ephrin/Eph system, the largest
receptor tyrosine kinase system in the human genome, may
give us a clue to unravel yet unknown pathogenesis of
AAA and to devise novel therapeutic strategies for AAA and
other inflammatory diseases, although specific roles of these
molecules in the development of AAA should further be
sought.
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